US Approves OraSure's
Rapid HIV Blood Test


WASHINGTON (Reuters) - U.S. officials have approved OraSure Technologies Inc.'s OraQuick HIV test, a blood test that delivers results in as little as 20 minutes, Health and Human Service Secretary Tommy Thompson said on Thursday.
"With this new test, in less than half an hour, (patients) can learn preliminary information about their HIV status, allowing them to get the care they need to slow the progression of their disease and to take precautionary measures to help prevent the spread of this deadly virus," he said.
Abbott Laboratories Inc. has an agreement with OraSure to help distribute the HIV test.
Orasure's shares rose 66 cents to $6.44, or 11.25 percent in midday trading on Nasdaq.
Abbot's shares were down 5 cents to $45.50 on the New York Stock Exchange.
Copyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.


This Site Served by TheHostPros